Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash & Equivalents for 7 consecutive years, with $357.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 196.88% to $357.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $357.0 million through Dec 2025, up 196.88% year-over-year, with the annual reading at $357.0 million for FY2025, 196.88% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $357.0 million at Kymera Therapeutics, up from $112.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $357.0 million in Q4 2025, with the low at $33.7 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $125.2 million, with a median of $89.2 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents tumbled 56.21% in 2021, then surged 396.68% in 2025.
  • Over 5 years, Cash & Equivalents stood at $48.0 million in 2021, then surged by 42.56% to $68.4 million in 2022, then skyrocketed by 60.78% to $110.0 million in 2023, then increased by 9.36% to $120.3 million in 2024, then surged by 196.88% to $357.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $357.0 million, $112.9 million, and $335.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.